Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ultragenyx Pharmaceutical Inc.

< Previous 1 2 3 Next >
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Participate at Investor Conferences in November
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Participate in the Jefferies London Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Proposed Public Offering of Common Stock
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers MREO RARE
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Participate at Investor Conferences in September
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers MREO RARE
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.